X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bilastine
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria, the Hyderabad-based company said in a regulatory filing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mometasone Furoate,Azelastine
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Momat Rino Advance
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy's Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment November 28, 2020
Details:
The divested brand and its extensions represent two types of products, (a) Mometasone mono product and (b) combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
